LIVN vs. TMDX, ITGR, INMD, CNMD, OM, BLFS, MASI, PRVB, MORF, and CVAC
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include TransMedics Group (TMDX), Integer (ITGR), InMode (INMD), CONMED (CNMD), Outset Medical (OM), BioLife Solutions (BLFS), Masimo (MASI), Provention Bio (PRVB), Morphic (MORF), and CureVac (CVAC). These companies are all part of the "medical" sector.
LivaNova vs.
LivaNova (NASDAQ:LIVN) and TransMedics Group (NASDAQ:TMDX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
LivaNova has a net margin of -7.83% compared to TransMedics Group's net margin of -23.76%. LivaNova's return on equity of 10.40% beat TransMedics Group's return on equity.
TransMedics Group has lower revenue, but higher earnings than LivaNova. TransMedics Group is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.
LivaNova received 294 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 69.57% of users gave LivaNova an outperform vote while only 53.24% of users gave TransMedics Group an outperform vote.
In the previous week, TransMedics Group had 3 more articles in the media than LivaNova. MarketBeat recorded 5 mentions for TransMedics Group and 2 mentions for LivaNova. LivaNova's average media sentiment score of 1.62 beat TransMedics Group's score of 0.85 indicating that LivaNova is being referred to more favorably in the media.
LivaNova has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.
98.9% of LivaNova shares are owned by institutional investors. Comparatively, 88.6% of TransMedics Group shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 6.7% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
LivaNova presently has a consensus price target of $64.60, indicating a potential upside of 46.75%. TransMedics Group has a consensus price target of $72.29, indicating a potential upside of 2.27%. Given LivaNova's higher possible upside, research analysts clearly believe LivaNova is more favorable than TransMedics Group.
Summary
LivaNova beats TransMedics Group on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LivaNova Competitors List
Related Companies and Tools